Spero Therapeutics Inc. [NASDAQ: SPRO] closed the trading session at $13.07 on 09/08/20. The day’s price range saw the stock hit a low of $8.90, while the highest price level was $14.30. The company report on September 8, 2020 that Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis.
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis.
Well-tolerated with comparable safety profile to intravenous ertapenem.
The stocks have a year to date performance of 35.93 percent and weekly performance of 20.24 percent. The stock has been moved at 48.52 percent over the last six months. The stock has performed 0.69 percent around the most recent 30 days and changed 3.24 percent over the most recent 3-months.
If compared to the average trading volume of 159.91K shares, SPRO reached to a volume of 3709130 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Spero Therapeutics Inc. [SPRO]:
H.C. Wainwright have made an estimate for Spero Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 05, 2019. The new note on the price target was released on September 09, 2019, representing the official price target for Spero Therapeutics Inc. stock. Previously, the target price had yet another raise to $27, while Cantor Fitzgerald analysts kept a Overweight rating on SPRO stock.
The Average True Range (ATR) for Spero Therapeutics Inc. is set at 1.15, with the Price to Sales ratio for SPRO stock in the period of the last 12 months amounting to 24.17. The Price to Book ratio for the last quarter was 3.66, with the Price to Cash per share for the same quarter was set at 3.29.
SPRO stock trade performance evaluation
Spero Therapeutics Inc. [SPRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.24. With this latest performance, SPRO shares gained by 0.69% in over the last four-week period, additionally plugging by 48.52% over the last 6 months – not to mention a rise of 17.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPRO stock in for the last two-week period is set at 58.06, with the RSI for the last a single of trading hit 63.59, and the three-weeks RSI is set at 55.31 for Spero Therapeutics Inc. [SPRO]. The present Moving Average for the last 50 days of trading for this stock 12.44, while it was recorded at 10.10 for the last single week of trading, and 10.74 for the last 200 days.
Spero Therapeutics Inc. [SPRO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Spero Therapeutics Inc. [SPRO] shares currently have an operating margin of -348.36. Spero Therapeutics Inc.’s Net Margin is presently recorded at -335.73.
Return on Total Capital for SPRO is now -64.51, given the latest momentum, and Return on Invested Capital for the company is -62.59. Return on Equity for this stock declined to -64.11, with Return on Assets sitting at -51.83. When it comes to the capital structure of this company, Spero Therapeutics Inc. [SPRO] has a Total Debt to Total Equity ratio set at 7.44. Additionally, SPRO Total Debt to Total Capital is recorded at 6.92, with Total Debt to Total Assets ending up at 5.23. Long-Term Debt to Equity for the company is recorded at 6.19, with the Long-Term Debt to Total Capital now at 5.76.
Reflecting on the efficiency of the workforce at the company, Spero Therapeutics Inc. [SPRO] managed to generate an average of -$1,068,860 per employee. Receivables Turnover for the company is 3.14 with a Total Asset Turnover recorded at a value of 0.15.Spero Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.50.
Earnings per share (EPS) analysis for Spero Therapeutics Inc. [SPRO] stock
With the latest financial reports released by the company, Spero Therapeutics Inc. posted -0.95/share EPS, while the average EPS was predicted by analysts to be reported at -0.85/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SPRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Spero Therapeutics Inc. go to 36.90%.
Spero Therapeutics Inc. [SPRO]: Insider Ownership positions
There are presently around $146 million, or 55.90% of SPRO stock, in the hands of institutional investors. The top three institutional holders of SPRO stocks are: AQUILO CAPITAL MANAGEMENT, LLC with ownership of 1,943,081, which is approximately 6.872% of the company’s market cap and around 0.30% of the total institutional ownership; ATLAS VENTURE ASSOCIATES IX, LLC, holding 1,376,968 shares of the stock with an approximate value of $18.0 million in SPRO stocks shares; and BLACKROCK INC., currently with $12.42 million in SPRO stock with ownership of nearly 7.833% of the company’s market capitalization.
Positions in Spero Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 62 institutional holders increased their position in Spero Therapeutics Inc. [NASDAQ:SPRO] by around 1,234,488 shares. Additionally, 21 investors decreased positions by around 1,004,538 shares, while 4 investors held positions by with 8,954,275 shares. The mentioned changes placed institutional holdings at 11,193,301 shares, according to the latest SEC report filing. SPRO stock had 28 new institutional investments in for a total of 376,549 shares, while 8 institutional investors sold positions of 647,029 shares during the same period.